Key result
Long-term aspirin lacks conclusive evidence for secondary ASCVD prevention, highlighting the need for withdrawal trials.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
John G.F. Cleland (2024) conducted an editorial in Chronic atherosclerotic cardiovascular disease (ASCVD). Aspirin vs. Placebo or no antiplatelet therapy was evaluated. Long-term administration of aspirin for secondary prevention of chronic atherosclerotic cardiovascular disease lacks conclusive evidence, highlighting the need for new placebo-controlled withdrawal trials.
Synapse has enriched 10 related papers. Consider them for comparative context: